

Description of Medical Areas
About the FDA Approved Listings
|
 |
Approved Drugs for Immunology/Infectious Diseases
Drugs Approved in 2008
Aptivus (tipranavir); For the treatment of HIV; Boehringer Ingelheim; Approved June 2008
Cinryze (C1 Inhibitor (Human)); For the treatment of angioedema attacks in adolescents/adults with Hereditary Angioedema; Lev Pharmaceuticals; Approved October 2008
Intelence (etravirine); For the treatment of HIV-1; Tibotec; Approved January 2008
Moxatag (amoxicillin); For the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatrics; MiddleBrooke Pharmaceuticals; Approved January 2008
Rotarix (Rotavirus Vaccine, Live, Oral); For the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) in pediatrics; GlaxoSmithKline; Approved April 2008
Tysabri (natalizumab); For the maintenance treatment of moderate to severe Crohn’s disease; Biogen IDEC; Approved January 2008
Viread (tenofovir disoproxil fumarate); For the treatment of hepatitis B; Gilead; Approved August 2008
Drugs Approved in 2007
Altabax (retapamulin); For the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes; Glaxo; Approved April 2007
AzaSite (azithromycin); For the treatment of bacterial conjunctivitis; InSite Vision; Approved April 2007
Doribax (doripenem); For the treatment of intra-abdominal infections and urinary tract infections; Johnson & Johnson; Approved October 2007
Extina (ketoconazole); For the treatment of seborrheic dermatitis; Stiefel; Approved June 2007
Isentress (raltegravir); For the treatment of HIV-1; Merck; Approved October 2007
Selzentry (maraviroc); For the treatment of CCR5-tropic HIV-1; Pfizer; Approved August 2007
Veramyst (fluticasone furoate); For the treatment of seasonal and perennial allergic rhinitis; GlaxoSmithKline; Approved April 2007
Drugs Approved in 2006
Eraxis (anidulafungin); For the treatment of Candida fungal infections; Pfizer; Approved February 2006
Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine); For the prevention of cervical cancer associated with human papillomavirus; Merck; Approved June 2006
Noxafil (posaconazole); For the treatment of fungal infections; Schering; Approved in September 2006
Prezista (darunavir); For the treatment of treatment-resistant HIV infections; Tibotec; Approved June 2006
Rotateq (rotavirus vaccine, live oral pentavalent); For the prevention of gastroenteritis associated with rotavirus infections in infants; Merck; Approved February 2006
Tyzeka (telbivudine); For the treatment of hepatitis B virus; Idenix Pharma; Approved October 2006
Drugs Approved in 2005
Aptivus (tipranavir); For the adjunctive treatment of HIV-1 infections; Boehringer Ingelheim; Approved June, 2005
Baraclude (entecavir); For the treatment of chronic hepatitis B infections with evidence of active viral replication; Bristol-Myers Squibb; Approved March, 2005
Drugs Approved in 2004
Ketek (telithromycin); For the treatment of infections caused by bronchitis, bacterial sinusitis and Community-acquired pneumonia.; Aventis Pharmaceuticals; Approved April 2004
Tindamax, tinidazole; For the treatment of microbial infections, including trichomoniasis, giardiasis, and amebiasis; Presutti Laboratories; Approved May, 2004
Xifaxan (rifaximin); For the treatment of Travelers' diarrhea caused by noninvasive strains of Escherichia coli; Salix Pharmaceuticals; Approved May 2004
Drugs Approved in 2003
Amevive (alefacept); For moderate to severe chronic plaque psoriasis.; Biogen; Approved January 2003
FluMist ( Influenza Virus Vaccine); For the prevention of disease caused by influenza A and B viruses; MedImmune; Approved June 2003
Fuzeon (enfuvirtide); For the treatment of HIV-1 infection in combination with other antiretroviral agents; Trimeris, Roche; Approved March 2003
Lexiva (fosamprenavir calcium); For the treatment of HIV infection in adults in combination with other antiretroviral agents.; GlaxoSmithKline; Approved October 2003
Reyataz (atazanavir sulfate); For the treatment of HIV-1 infection in combination with other antiretroviral agents; Bristol-Myers Squibb; Approved July 2003
Drugs Approved in 2002
Alinia (nitazoxanide); For the treatment Diarrhea caused by Cryptosporidium and Giardia in children.; Romark Laboratories; December 2002
Clarinex; Once-daily oral tablet for the treatment of allergic rhinitis and chronic ideopathic urticaria; Schering-Plough; Approved February 2002
Daptacel; Pediatric vaccine for immunization against diptheria, tetanus and pertussis; Aventis Pasteur; Approved May 2002
Fluzone Preservative-free; Preservative free, pediatric dose, influenza virus vaccine for the immunization of infants; Aventis Pasteur; Approved September 2002
Hepsera (adefovir dipivoxil); For the treatment of chronic hepatitis B in adults with evidence of active viral replication; Gilead Sciences; Approved September 2002
Pediarix Vaccine; For the prevention of diphtheria, tetanus, pertussi, polio and hepatitis B in children 6 weeks to 7 years old.; GlaxoSmithKline; Approved December 2002
Pegasys (peginterferon alfa-2a); For the treatment of chronic hepatitis C who have compensated liver disease; Roche; Approved October 2002
Restasis (cyclosporine ophthalmic emulsion); For the treatment of low tear production.; Allergan; December 2002
Sustiva; Once-daily oral tablet for the the treatment of HIV infection; Bristol-Myers Squibb; Approved February 2002
Drugs Approved in 2001
Avelox I.V. (moxifloxacin hydrochloride); Injectable antibacterial agent for adults with susceptible strains of bacterial infections; Bayer; Approved November 2001
Cancidas; Intravenous infusion for the treatment of invasive aspergillosis; Merck; Approved January 2001
Peg-Intron (peginterferon alfa-2b); For the treatment of chronic hepatitis C; Schering-Plough; Approved January 2001
Rebetol (ribavirin); For the treatment of chronic hepatitis C; Schering-Plough; Approved July 2001
Spectracef; Oral tablets for the treatment of mild to moderate bacterial infections; TAP Pharmaceuticals; Approved August 2001
Twinrix; For the prevention of hepatitis A and B; GlaxoSmithKline; Approved May 2001
Valcyte (valganciclovir HCl); For the treatment of cytomegalovirus retinitis in patients with AIDS; Roche; Approved March 2001
Viread; Once-daily oral tablet for the treatment of human immunodeficiency virus (HIV) infection; Gilead Sciences; Approved October 2001
Drugs Approved in 2000
ABREVA (docosanol); Cold sore/fever blister; AVANIR PHARMACEUTICALS; Approved July 2000
Biaxin XL (clarithromycin extended-release tablets); For Acute Bacterial Exacerbation of Chronic Bronchitis (AECB) and Acute Maxillary Sinusitis; Abbott Laboratories; Approved March 2000
Cefazolin and Dextrose USP; Respiratory tract infections; B Braun Medical; Approved July 2000
Children's Motrin Cold; For temporary relief of the common cold; McNeil Consumer Products; Approved August 2000
Evoxac; For the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome; SnowBrand Pharmaceuticals; Approved January 2000
Kaletra Capsules and Oral Solution; For the treatment of HIV-1 infection; Abbott Laboratories; Approved September 2000
Lamisil (terbinafine hydrochloride) Solution, 1%; For the treatment of athlete's foot, jock itch and ringworm; Novartis; Approved March 2000
Lotrisone (clotrimazole/betamethasone diproprionate) lotion; For the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis; Schering-Plough; Approved December 2000
Malarone (atovaquone; proguanil hydrochloride) Tablet; For the treatment and prevention of Plasmodium falciparum malaria; GlaxoWellcome; Approved July 2000
Rapamune (sirolimus) Tablets; For treatment of kidney rejection; Wyeth-Ayerst Laboratories; Approved August 2000
Rid Mousse; For the treatment of head, pubic (crab), and body lice; Soltec Research; Approved March 2000
Tri-Nasal Spray (triamcinolone acetonide spray); For treatment of nasal symptoms of allergic rhinitis in adults and children age 12 or older; Muro Pharmaceutical; Approved February 2000
Trivagizole 3 (clotrimazole) Vaginal Cream; For the treatment of vaginal yeast infections; Taro Pharmaceuticals; Approved April 2000
Drugs Approved in 1999
Agenerase (amprenavir); For the treatment of HIV-1 infection.; GlaxoWellcome; Approved April 1999
Cleocin; Treatment for bacterial vaginosis; Pharmacia & Upjohn; Approved August 1999
Famvir; Treatment for Herpes Simplex Infections in HIV-infected patients; SmithKline Beecham; Approved January 1999
Norvir (ritonavir) soft-gel capsules; Treatment for HIV infection; Abbott Laboratories; Approved June 1999
Panretin Gel; Treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.; Ligand Pharmaceuticals; Approved June 1999
Rapamune; Oral solution of sirolimus; Wyeth-Ayerst Laboratories; Approved September 1999
Relenza; Treatment for uncomplicated acute illness due to influenza virus; GlaxoWellcome; Approved July 1999
Synercid I.V.; quinupristin and dalfopristin for injection; Rhone Poulenc Rorer; Approved September 1999
Tamiflu capsule; Oseltamivir phosphate capsule; Roche; October 27, 1999
Vistide; For the treatment of cytomegalovirus (CMV) retinitis; Gilead Sciences; Approved March 1999
Drugs Approved in 1998
Allegra-D; Treatment for nasal congestion due to seasonal allergy; Hoechst Marion Roussel; Approved March 1998
CellCept; Treatment for the prevention of organ rejection inpatients undergoing heart transplants; Roche; Approved February 1998
Clemastine fumarate syrup; Generic equivalent of Tavist Syrup; Morton Grove Pharmaceuticals; Approved March 1998
Cleocin Vaginal Cream 2%; Treatment for bacterial vaginosis; Pharmacia & Upjohn; Approved March 1998
Dynabac; Treatment for acute bacterial exacerbations (chronic bronchitis and skin infections); Sanofi Pharmaceuticals; Approved March 1998
REBETRON (TM) Combination Therapy; Treatment for Chronic Hepatitis C; Schering-Plough; Approved June 1998
Simulect; Treatment for acute organ transplant rejection; Novartis; Approved May 1998
Timentin; Treatment for wide range of infections in children; SmithKline Beecham; Approved January 1998
Viroptic; Treatment for inflammation of the cornea in children due to herpes simplex virus; King Pharmaceuticals; Approved February 1998
Drugs Approved in 1997
|